Pulmatrix, Inc. (PULM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pulmatrix, Inc. (PULM) trades at $1.50 with AI Score 26/100 (Grade F). Pulmatrix, Inc. is a clinical-stage biotechnology company focused on developing inhaled therapies for respiratory diseases. Market cap: $5.48M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PULM: PULM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PULM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PULM: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Pulmatrix, Inc. (PULM) Healthcare & Pipeline Overview
Pulmatrix, Inc. is a clinical-stage biotech firm leveraging its iSPERSE technology to create inhaled therapies for respiratory diseases like asthma, COPD, and fungal infections. The company's pipeline includes Pulmazole, PUR1800, and PUR3100, targeting unmet needs in pulmonary medicine, while facing competition from established pharmaceutical companies.
What Is the Investment Thesis for PULM?
Pulmatrix, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's iSPERSE technology offers a novel approach to drug delivery for respiratory diseases, potentially improving treatment outcomes and patient compliance. Key value drivers include the successful clinical development and commercialization of Pulmazole for ABPA, PUR1800 for COPD, and PUR3100 for acute migraine. Upcoming milestones include the progression of PUR1800 through Phase 2 clinical trials and the potential for strategic partnerships to further develop and commercialize its pipeline assets. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market cap of $5.48M and a negative P/E ratio of -1.49, Pulmatrix's valuation reflects the speculative nature of its pipeline and the inherent risks associated with early-stage biotechnology companies.
Based on FMP financials and quantitative analysis
PULM Key Highlights
Pulmatrix's iSPERSE technology allows for targeted drug delivery to the lungs, potentially improving efficacy and reducing systemic side effects.
- Pulmazole, an inhaled anti-fungal drug, is being developed for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma and cystic fibrosis.
- PUR1800, a narrow spectrum kinase inhibitor, is currently in Phase 1b clinical trials for patients with stable moderate-to-severe chronic obstructive pulmonary disease (COPD).
- PUR3100, an iSPERSE formulation of dihydroergotamine, is being developed for the treatment of acute migraine.
- The company has a market capitalization of $5.48M as of March 17, 2026.
Who Are PULM's Competitors?
PULM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASBP Aspire Biopharma Holdings, Inc. | $7.82 | -1.01% | — | |
| CTXR Citius Pharmaceuticals, Inc. | $0.60 | -5.91% | $6.70M | — |
| DARE Daré Bioscience, Inc. | $0.81 | -1.84% | $12.1M | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PULM's Key Strengths?
Proprietary iSPERSE technology for targeted drug delivery.
- Pipeline of inhaled therapies for respiratory diseases and migraine.
- Established partnerships with pharmaceutical companies.
- Experienced management team with expertise in drug development.
What Are PULM's Weaknesses?
Limited financial resources.
- Dependence on clinical trial outcomes and regulatory approvals.
- Small number of employees.
- Limited commercialization experience.
What Could Drive PULM Stock Higher?
Phase 2 clinical trial results for PUR1800 in COPD patients.
- Potential partnership or licensing agreement for Pulmazole.
- Advancement of PUR3100 through clinical development for acute migraine.
- Continued development and optimization of iSPERSE technology.
What Are the Key Risks for PULM?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Pulmazole, PUR1800, or PUR3100.
- Regulatory delays or rejection of marketing applications.
- Competition from established pharmaceutical companies.
- Limited financial resources and dependence on external funding.
- Patent expiration and loss of exclusivity for key products.
What Are the Growth Opportunities for PULM?
- Pulmazole for Allergic Bronchopulmonary Aspergillosis (ABPA): The market for ABPA treatment is underserved, with limited effective therapies available. Pulmatrix's Pulmazole, an inhaled anti-fungal drug, has the potential to become a leading treatment option for ABPA in patients with asthma and cystic fibrosis. Successful clinical trials and regulatory approval could drive significant revenue growth for Pulmatrix. The timeline for potential commercialization is dependent on clinical trial outcomes and regulatory review, but could be within the next 3-5 years.
- PUR1800 for Chronic Obstructive Pulmonary Disease (COPD): COPD is a major global health problem, and there is a need for new and effective treatments. PUR1800, a narrow spectrum kinase inhibitor, is currently in Phase 1b clinical trials for COPD. Positive clinical data could lead to further development and commercialization, addressing a large and growing market.
- PUR3100 for Acute Migraine: The acute migraine market is a significant opportunity, with a large patient population seeking effective and convenient treatments. PUR3100, an iSPERSE formulation of dihydroergotamine, offers a potential advantage over existing migraine medications by providing rapid and targeted drug delivery. Successful clinical development and commercialization could drive significant revenue growth for Pulmatrix. The timeline for potential commercialization is dependent on clinical trial outcomes and regulatory review.
- Strategic Partnerships and Licensing Agreements: Pulmatrix has a history of establishing strategic partnerships and licensing agreements to advance its programs. Further collaborations with pharmaceutical companies or other biotechnology firms could provide access to additional funding, expertise, and resources, accelerating the development and commercialization of its pipeline assets. These partnerships can also validate the value of Pulmatrix's iSPERSE technology and pipeline candidates.
- Expansion into New Therapeutic Areas: While Pulmatrix is currently focused on respiratory diseases and migraine, its iSPERSE technology could be applied to other therapeutic areas, such as pulmonary hypertension or lung cancer. Expanding into new therapeutic areas could diversify the company's pipeline and create new growth opportunities. This would require further research and development efforts, but could significantly increase the long-term value of the company.
What Are PULM's Competitive Advantages?
- Proprietary iSPERSE technology for inhaled drug delivery.
- Patent protection on its drug formulations and delivery methods.
- Established partnerships with pharmaceutical companies.
- Clinical data supporting the efficacy and safety of its therapies.
What Does PULM Do?
Founded in 2003 and headquartered in Lexington, Massachusetts, Pulmatrix, Inc. is a biotechnology company dedicated to discovering and developing innovative inhaled therapies for respiratory and other diseases with unmet medical needs. The company's core technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), enables the delivery of both small and large molecule drugs directly to the lungs through inhalation. This targeted approach aims to improve efficacy and reduce systemic side effects compared to traditional oral or injectable medications. Pulmatrix's product pipeline includes Pulmazole, an inhaled anti-fungal drug being developed for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma and cystic fibrosis. Additionally, PUR1800, a narrow spectrum kinase inhibitor, is currently in Phase 1b clinical trials for patients with stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100, an iSPERSE formulation of dihydroergotamine, is being developed for the treatment of acute migraine. Pulmatrix has established strategic partnerships to advance its programs, including a license agreement with RespiVert Ltd. for access to kinase inhibitor drug candidates, a development and commercialization agreement with Cipla Technologies LLC for Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc.
What Products and Services Does PULM Offer?
- Develops inhaled therapies for respiratory diseases.
- Utilizes iSPERSE technology for targeted drug delivery to the lungs.
- Creates treatments for conditions like asthma, COPD, and ABPA.
- Formulates inhaled anti-fungal drugs.
- Develops narrow spectrum kinase inhibitors.
- Formulates dihydroergotamine for acute migraine treatment.
How Does PULM Make Money?
- Develops pharmaceutical products using its proprietary iSPERSE technology.
- Out-licenses or partners with other pharmaceutical companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties on product sales.
- Focuses on research and development to create new inhaled therapies.
What Industry Does PULM Operate In?
The biotechnology industry is characterized by high innovation, lengthy development timelines, and significant regulatory oversight. The market for inhaled therapies is driven by the increasing prevalence of respiratory diseases such as asthma, COPD, and cystic fibrosis. Pulmatrix operates in a competitive landscape with established pharmaceutical companies and other biotechnology firms developing novel treatments for these conditions. The company's iSPERSE technology offers a potential competitive advantage by enabling targeted drug delivery and improved patient outcomes.
Who Are PULM's Key Customers?
- Pharmaceutical companies that license or partner with Pulmatrix.
- Patients suffering from respiratory diseases and migraine who use Pulmatrix's therapies (indirectly).
- Healthcare providers who prescribe Pulmatrix's therapies.
Company Profile
Pulmatrix, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Framingham, US. The company is led by CEO Peter Ludlum. PULM has traded publicly since 2014.
How Pulmatrix, Inc. Is Valued
Pulmatrix, Inc. carries a market capitalization of $5.48M, placing it in the micro-cap category. Relative to its peer group, PULM's quantitative score of 26/100 is below the peer average of 77/100.
Key Financial Metrics
Its free cash flow yield is -83.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -81.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Pulmatrix, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Pulmatrix, Inc. revenue of about $16.5M for fiscal 2026, with EPS near $-2.24.
Insider Activity
The most recent 10 insider filings for Pulmatrix, Inc. break down as 0 sales and 10 purchases. On net that is roughly 123K shares acquired (about $14K) — insiders putting money in tends to read as conviction.
PULM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Pulmatrix's future prospects, indicating that key stakeholders believe in the company's direction.
- Community sentiment has been increasingly positive, with discussions around potential breakthroughs in respiratory therapies gaining traction.
- Analysts have highlighted the unique position of Pulmatrix in the respiratory health market, which could attract more attention from investors.
- The recent partnerships formed by Pulmatrix to enhance product development signal a strategic move towards growth and innovation.
Bear Case
- Despite positive sentiment, some analysts remain cautious due to the competitive landscape in the biotech sector, which could impact Pulmatrix's market share.
- Recent discussions in the community also reflect skepticism about the company's ability to deliver on its promises in a timely manner.
- There are concerns regarding the company's cash runway, as sustaining operations without significant revenue can pose risks.
- Market perception remains mixed, with some investors worried about the overall volatility in the biotech market affecting Pulmatrix's stability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PULM Latest News
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Jun 29, 2026
PULM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PULM.
Price Targets
Wall Street price target analysis for PULM.
PULM MoonshotScore
What does this score mean?
The MoonshotScore rates PULM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Peter Ludlum
CEO
Peter Ludlum serves as the Chief Executive Officer of Pulmatrix, Inc. His leadership is pivotal in guiding the company's strategic direction and overseeing the development of its innovative inhaled therapies. Given the limited number of employees, his role likely encompasses a wide range of responsibilities, from strategic planning to operational execution. Additional background information is not available in the provided data.
Track Record: Due to the limited information available, Peter Ludlum's specific achievements and milestones at Pulmatrix, Inc. cannot be detailed. However, as CEO, he is responsible for driving the company's clinical development programs, securing partnerships, and managing the overall financial performance. His success is tied to the advancement of Pulmatrix's pipeline candidates and the creation of shareholder value.
PULM Healthcare Stock FAQ
What does the AI Score mean for PULM?
PULM holds an AI Score of 26/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Pulmatrix, Inc. is a clinical-stage biotechnology company focused on developing inhaled therapies for respiratory diseases. Their iSPERSE technology aims to deliver drugs directly to the lungs …
What does Pulmatrix, Inc. do?
Pulmatrix, Inc. is a clinical-stage biotechnology company focused on developing inhaled therapies for respiratory diseases and other conditions. The company's proprietary iSPERSE technology enables targeted drug delivery to the lungs, potentially improving efficacy and reducing systemic side effects. Pulmatrix's pipeline includes Pulmazole for allergic bronchopulmonary aspergillosis (ABPA), PUR1800 for chronic obstructive pulmonary disease (COPD), and PUR3100 for acute migraine.
What are the main risks for PULM?
Pulmatrix, Inc. faces several key risks typical of a clinical-stage biotechnology company. Clinical trial failures represent a significant risk, as negative results for Pulmazole, PUR1800, or PUR3100 could halt development and significantly impact the company's valuation. Regulatory hurdles and potential delays in obtaining marketing approvals also pose a risk.
What are the key factors to evaluate for PULM?
Pulmatrix, Inc. (PULM) holds an AI score of 26/100 (low). presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does PULM data refresh on this page?
PULM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PULM's recent stock price performance?
Pulmatrix, Inc. (PULM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary iSPERSE technology for targeted drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PULM overvalued or undervalued right now?
Pulmatrix, Inc. (PULM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PULM before investing?
Before investing in Pulmatrix, Inc. (PULM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PULM to a portfolio?
Key strength of Pulmatrix, Inc. (PULM): Proprietary iSPERSE technology for targeted drug delivery. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data provided.
- AI analysis is pending, so analyst consensus is unavailable.
- Financial metrics are based on current market data and may fluctuate.